BR9913553A - Formulação de ranolazina de liberação sustentada - Google Patents

Formulação de ranolazina de liberação sustentada

Info

Publication number
BR9913553A
BR9913553A BR9913553-1A BR9913553A BR9913553A BR 9913553 A BR9913553 A BR 9913553A BR 9913553 A BR9913553 A BR 9913553A BR 9913553 A BR9913553 A BR 9913553A
Authority
BR
Brazil
Prior art keywords
ranolazine
sustained release
release formulation
formation
aqueous medium
Prior art date
Application number
BR9913553-1A
Other languages
English (en)
Inventor
Andrew A Wolff
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9913553(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of BR9913553A publication Critical patent/BR9913553A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"FORMULAçãO DE RANOLAZINA DE LIBERAçãO SUSTENTADA". Uma formulação de ranolazina de contém uma mistura íntima de ranolazina e um aglutinante dependente de pH parcialmente neutralizado, para a formação de um filme, que é praticamente insolúvel em um meio aquoso com pH abaixo de 4, 5 e solúvel em um meio aquoso com pH acima de 4,5 . A formulação é adequada para uma administração duas vezes ao dia de ranolazina, e é útil para o controle da taxa de dissolução de ranolazina, e para manter os níveis de ranolazina de plasma humano entre 550 e 7500 ng base/mL.
BR9913553-1A 1998-09-10 1999-09-09 Formulação de ranolazina de liberação sustentada BR9913553A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation
PCT/US1999/020968 WO2000013687A2 (en) 1998-09-10 1999-09-09 Sustained release ranolazine formulations

Publications (1)

Publication Number Publication Date
BR9913553A true BR9913553A (pt) 2001-10-23

Family

ID=26796494

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9913553-1A BR9913553A (pt) 1998-09-10 1999-09-09 Formulação de ranolazina de liberação sustentada
BR9913626-0A BR9913626A (pt) 1998-09-10 1999-09-09 Formulações de ranolazina de liberação contìnua

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9913626-0A BR9913626A (pt) 1998-09-10 1999-09-09 Formulações de ranolazina de liberação contìnua

Country Status (33)

Country Link
US (14) US6303607B1 (pt)
EP (3) EP1527779A1 (pt)
JP (2) JP3745621B2 (pt)
KR (1) KR100475759B1 (pt)
CN (2) CN1193757C (pt)
AR (3) AR022085A1 (pt)
AT (2) ATE285774T1 (pt)
AU (4) AU760435B2 (pt)
BR (2) BR9913553A (pt)
CA (2) CA2342390C (pt)
CY (1) CY2008020I1 (pt)
CZ (2) CZ301341B6 (pt)
DE (3) DE69922964T2 (pt)
DK (2) DK1096937T3 (pt)
ES (2) ES2177346T3 (pt)
FR (1) FR09C0001I2 (pt)
GE (1) GEP20053420B (pt)
HK (2) HK1040060A1 (pt)
HU (2) HUP0104088A3 (pt)
IL (6) IL141893A0 (pt)
LU (1) LU91504I2 (pt)
MX (2) MXPA01002599A (pt)
NL (1) NL300371I2 (pt)
NO (4) NO319434B1 (pt)
NZ (2) NZ510386A (pt)
PL (3) PL202207B1 (pt)
PT (2) PT1096937E (pt)
RU (2) RU2207856C2 (pt)
SI (2) SI1109558T1 (pt)
TR (2) TR200101262T2 (pt)
TW (1) TWI241911B (pt)
UA (2) UA75027C2 (pt)
WO (2) WO2000013687A2 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
IL151014A0 (en) * 2000-02-18 2003-02-12 Cv Therapeutics Inc Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
WO2003084517A2 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules d’amoxicilline
CN100551370C (zh) 2002-05-21 2009-10-21 Cv医药有限公司 雷诺嗪在制备治疗糖尿病的药物组合物中的应用
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
CN101098682A (zh) * 2005-01-06 2008-01-02 Cv医药有限公司 包括雷诺嗪的缓释药物制剂
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
JP2009502957A (ja) * 2005-07-28 2009-01-29 スパーナス ファーマシューティカルズ インコーポレイテッド 機械的特性の向上した徐放性錠剤配合物
US20090091253A1 (en) * 2006-03-17 2009-04-09 Konica Minolta Holdings, Inc. Organic electroluminescent element, display device and lighting device
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
CA2677931A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
CA2678325A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
ES2395241T3 (es) * 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20080299195A1 (en) * 2007-05-31 2008-12-04 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
JP2010529994A (ja) * 2007-06-13 2010-09-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ピペラジン
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
AU2010248948A1 (en) * 2009-05-14 2011-12-01 Gilead Sciences, Inc. Ranolazine for the treatment of CNS disorders
EP2515880B1 (en) 2009-05-28 2019-11-27 Lupin Limited Novel pharmaceutical compositions of ranolazine
MX2012003362A (es) * 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
EP2524688B1 (en) 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
NO3175985T3 (pt) 2011-07-01 2018-04-28
EP2758053A1 (en) 2011-09-21 2014-07-30 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
WO2014176557A2 (en) * 2013-04-26 2014-10-30 Chanrx Corporation Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rythm in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
AU633589B2 (en) * 1989-06-23 1993-02-04 Syntex (U.S.A.) Inc. Novel methods of treatment using ranolazine and related piperazine derivatives
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation

Also Published As

Publication number Publication date
SI1096937T1 (en) 2005-04-30
NO2009005I2 (pt) 2010-06-28
EP1096937A2 (en) 2001-05-09
IL175371A0 (en) 2006-09-05
NZ510384A (en) 2002-10-25
CZ301375B6 (cs) 2010-02-03
US6503911B2 (en) 2003-01-07
EP1096937B1 (en) 2004-12-29
WO2000013686A3 (en) 2000-07-06
KR20010089874A (ko) 2001-10-12
IL180864A0 (en) 2007-07-04
SI1109558T1 (en) 2002-10-31
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
US6525057B2 (en) 2003-02-25
US6369062B1 (en) 2002-04-09
TR200101261T2 (tr) 2002-05-21
HUP0104088A2 (hu) 2002-05-29
CZ2001879A3 (cs) 2001-08-15
GEP20053420B (en) 2005-01-25
CA2342390A1 (en) 2000-03-16
ATE285774T1 (de) 2005-01-15
RU2214233C2 (ru) 2003-10-20
HK1044284A1 (en) 2002-10-18
US20030166659A1 (en) 2003-09-04
NO320986B1 (no) 2006-02-20
US20040097514A1 (en) 2004-05-20
DK1096937T3 (da) 2005-05-09
AU760435B2 (en) 2003-05-15
RU2207856C2 (ru) 2003-07-10
JP2006096757A (ja) 2006-04-13
US20020090396A1 (en) 2002-07-11
HUP0103844A3 (en) 2002-11-28
IL141892A (en) 2006-08-20
PL202207B1 (pl) 2009-06-30
US20050153982A1 (en) 2005-07-14
AR022085A1 (es) 2002-09-04
CN1193757C (zh) 2005-03-23
NL300371I2 (nl) 2009-10-01
AU6036499A (en) 2000-03-27
AR052921A1 (es) 2007-04-11
DK1109558T3 (da) 2002-08-26
PL196263B1 (pl) 2007-12-31
US20020004506A1 (en) 2002-01-10
DE69901570D1 (de) 2002-06-27
AU744071B2 (en) 2002-02-14
US6864258B2 (en) 2005-03-08
UA67793C2 (uk) 2004-07-15
HUP0104088A3 (en) 2002-12-28
WO2000013687A3 (en) 2000-06-29
CZ301341B6 (cs) 2010-01-20
US20040029890A1 (en) 2004-02-12
TWI241911B (en) 2005-10-21
NO20011192D0 (no) 2001-03-08
HK1044284B (zh) 2005-07-15
NO319434B1 (no) 2005-08-15
US20050059667A1 (en) 2005-03-17
US6620814B2 (en) 2003-09-16
TR200101262T2 (tr) 2001-12-21
NO20011192L (no) 2001-04-30
DE69901570T2 (de) 2003-01-09
US20060217397A1 (en) 2006-09-28
DE69922964T2 (de) 2005-12-08
IL141893A (en) 2008-08-07
US20030100566A1 (en) 2003-05-29
HU224215B1 (hu) 2005-06-28
MXPA01002598A (es) 2002-04-08
PL196668B1 (pl) 2008-01-31
EP1527779A1 (en) 2005-05-04
NL300371I1 (nl) 2009-02-02
AU2008207707A1 (en) 2008-09-25
PL348249A1 (en) 2002-05-20
EP1096937B9 (en) 2007-02-28
DE122008000065I1 (de) 2009-04-09
CN1354665A (zh) 2002-06-19
CY2008020I2 (el) 2010-07-28
FR09C0001I1 (pt) 2009-02-27
ES2234302T3 (es) 2005-06-16
US6852724B2 (en) 2005-02-08
FR09C0001I2 (pt) 2009-12-18
US6617328B2 (en) 2003-09-09
EP1109558A2 (en) 2001-06-27
CY2008020I1 (el) 2010-07-28
CA2343376C (en) 2007-01-09
US20060147521A1 (en) 2006-07-06
EP1109558B1 (en) 2002-05-22
JP3745621B2 (ja) 2006-02-15
AU6142599A (en) 2000-03-27
US6303607B1 (en) 2001-10-16
US6562826B1 (en) 2003-05-13
AU2008207703A1 (en) 2008-09-25
NO20011191L (no) 2001-04-30
JP2002524416A (ja) 2002-08-06
ES2177346T3 (es) 2002-12-01
CA2343376A1 (en) 2000-03-16
IL141892A0 (en) 2002-03-10
CZ2001880A3 (cs) 2001-08-15
WO2000013687A2 (en) 2000-03-16
CN1211086C (zh) 2005-07-20
US20030099705A1 (en) 2003-05-29
LU91504I9 (pt) 2019-01-02
BR9913626A (pt) 2001-12-04
MXPA01002599A (es) 2005-02-17
AR053440A2 (es) 2007-05-09
ATE217794T1 (de) 2002-06-15
CN1321088A (zh) 2001-11-07
NO20011191D0 (no) 2001-03-08
IL141893A0 (en) 2002-03-10
NO2009005I1 (no) 2009-03-16
LU91504I2 (fr) 2009-02-03
HK1040060A1 (en) 2002-05-24
KR100475759B1 (ko) 2005-03-10
PT1109558E (pt) 2002-10-31
UA75027C2 (uk) 2006-03-15
PT1096937E (pt) 2005-04-29
NO20054324L (no) 2001-04-30
NZ510386A (en) 2003-08-29
HUP0103844A2 (hu) 2002-04-29
CA2342390C (en) 2006-08-29
DE69922964D1 (de) 2005-02-03

Similar Documents

Publication Publication Date Title
BR9913553A (pt) Formulação de ranolazina de liberação sustentada
BR0109091A (pt) Formulações de ranolazina de liberação sustentada
BR0202375A (pt) Composições farmacêutica compreendendo drogas e polìmeros de aumento da concentração
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
YU47204B (sh) Derivati didehidro-vitamina d3
BR0016555A (pt) Composições farmacêuticas que proporcionam concentrações acrescidas de droga
DK0850046T3 (da) Mikroemulsioner til anvendelse som vhikel til indgift af active forbindelser
PT814782E (pt) Composicao farmaceutica estabilizada com um agente basico
NO974615L (no) Emulsjon som egner seg for administrering av lite vannopplöselige, fotosensitiserende forbindelser, samt anvendelse derav
ES2111547T3 (es) Comprimido de liberacion prolongada.
ES2105551T3 (es) Utilizacion de derivados de la resorcina substituidos en posicion(es) 4,4 y 5 o 4 y 6 en unas composiciones cosmeticas o dermofarmaceuticas con accion despigmentante.
GB9514518D0 (en) Guanidine salt inhibitors of NO synthase and cyclooxygenase
ES8101537A1 (es) Un procedimiento para preparar nuevas fenetanolaminas
DK0973546T3 (da) Stabiliserede formuleringer med human papillomavirus
NO971860D0 (no) Matrikstablett som tillater en forlenget frigivelse av natriumsaltet av tianeptin etter oral administrasjon
AU5727899A (en) Diaminocyclobutene-3,4-dione derivatives, their preparation and use
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
BR0215125A (pt) Emulsão óleo-em-água
DE69302829T2 (de) Bicyclische pyrimidinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate
HUP0000961A2 (hu) Nedvesíthető vagy vízoldható granulált agrokémiai készítmény
BR9811177A (pt) Composto, composição farmacêutica, e, uso do composto
WO1999031054A3 (de) NEUE p-AMINOPHENOL-DERIVATE UND DEREN VERWENDUNG
EP1197212A4 (en) ADHESIVE COMPOSITION FOR PERCUTANE ABSORPTION
CA2010085A1 (en) Pentamidine solutions
AU6675794A (en) Benzo(F)quinoxalindione derivatives, their preparation and their use in drugs

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: ROCHE PALO ALTO LLC (US)

Free format text: TRANSFERIDO DE: CV THERAPEUTICS, INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8 E 13 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.